Compare SRPT & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | ASH |
|---|---|---|
| Founded | 1980 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2000 | 2016 |
| Metric | SRPT | ASH |
|---|---|---|
| Price | $22.77 | $54.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 28 | 7 |
| Target Price | $25.40 | ★ $65.57 |
| AVG Volume (30 Days) | ★ 3.2M | 593.2K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,198,237,000.00 | $1,824,000,000.00 |
| Revenue This Year | N/A | $2.41 |
| Revenue Next Year | N/A | $3.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $45.21 |
| 52 Week High | $64.80 | $65.65 |
| Indicator | SRPT | ASH |
|---|---|---|
| Relative Strength Index (RSI) | 64.87 | 48.89 |
| Support Level | $20.61 | $53.45 |
| Resistance Level | $23.51 | $54.56 |
| Average True Range (ATR) | 1.30 | 1.74 |
| MACD | 0.59 | 0.78 |
| Stochastic Oscillator | 85.75 | 75.53 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.